RBC Life Sciences' Sales and Earnings Increased 26 Percent during the Third Quarter of 2008
Irving, Texas (RBC Life Sciences: OTCBB: RBCL) — RBC Life Sciences Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported net sales of $9.93 million for the quarter ended September 30, 2008—a 26 percent increase over net sales of $7.86 million for the same period last year.
RBC Life Sciences recorded net earnings of $846,000, or $0.04 per share, during the third quarter of 2008—a 26 percent increase over net earnings of $672,000, or $0.03 per share, during the third quarter of 2007.
"International licensee sales for the quarter increased 36 percent over sales in the same quarter last year," said RBC Life Sciences founder and CEO, Clinton Howard. "Considering current economic conditions, the company is fortunate to have ample working capital to finance this rate of growth. The company also has a healthy balance sheet whose only debt consists of the company's mortgage on its headquarters facility."
The company's MPM Medical Inc. brand of medical devices also continued to grow strongly. Sales of MPM's evidence-based prescription and non-prescription wound care and pain management products increased 42 percent over the same period last year.
The growth comes at a time when the company has refocused efforts to grow its U.S. and Canadian markets while embarking on aggressive international expansion.
About RBC Life Sciences
RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products to a growing population of consumers seeking wellness and a healthy lifestyle. Under its MPM Medical brand, RBC Life Sciences also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the Company's Web site at www.rbclifesciences.com.
The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange.
search blogs
share it
blog it
